

DAFTAR PUSTAKA

- Allen, H. D., Driscoll, D. J., Shaddy, R. E. 2016. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. Baltimore, MD: Lippincott Williams & Wilkins Co, Philadelphia.
- Al-hitti, H., Melenovsky, V., Syrovatka, P., Kettner, J., Malek, I., Kautzner, J. 2011. Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure. *Physiol Res.* 60:303-308
- Apitz, C., Hansmann, G. dan Schranz, D. 2016. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart*, 102: ii23–ii29.
- Augustine, D. X., Coates-Bradshaw, L. D., Willis, J., Harkness, A., Ring, L., Grapsa, J., Coghlan, G., Kaye, N., Oxborough, D. dan Robinson, S. 2018. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo research and practice*, 5: G11–G24.
- Barnett, C. F. dan Machado, R. F. 2006. Sildenafil in the treatment of pulmonary hypertension. : 411–422.
- Barst, R. J., Agnoletti, G., Fraisse, A., Baldassarre, J., Wessel, D. L. dan Group, N. O. D. S. 2010. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. *Pediatric cardiology*, 31: 598–606.
- Barst, R. J., Gibbs, J. S. R., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Rubin, L. J., Sitbon, O., Tapon, V. F. dan Galie, N. 2009. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, 54: S78-84.
- Baumgartner, H., De Backer, J., Babu-Narayan, S. V., Budts, W., Chessa, M., Diller, G.-P., Lung, B., Kluin, J., Lang, I. M. dan Meijboom, F. 2020. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J.*
- Beghetti, M. dan Galiè, N. 2009. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, 53: 733–740.
- Bharani, A., Mathew, V., Sahu, A. dan Lunia, B. 2003. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. *Indian heart journal*, 55: 55–59.
- Bossone, E., Bodini, B. D., Mazza, A. dan Allegra, L. 2005. Pulmonary arterial hypertension: the key role of echocardiography. *Chest*, 127: 1836–1843.
- Cevik, A., Kula, S., Olgunturk, R., Tunaoglu, S., Oguz, D., Saylan, B. dan Sanli, C. 2014. Evaluation of pulmonary vascular resistance and vasoreactivity testing with oxygen in children with congenital heart disease and pulmonary arterial hypertension. *Anadolu kardiyoloji dergisi : AKD = the Anatolian*

journal of cardiology, 14: 196–198.

- Chau, E. M. C., Fan, K. Y. Y. dan Chow, W. H. 2007. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. *International journal of cardiology*, 120: 301–305.
- Cheng, X., Xiong, C., He, J., Liu, Z., Gu, Q., Ni, X., Zhao, Z. dan Luo, Q. 2016. Impact of systemic hypertension on clinical outcome of patients with idiopathic pulmonary arterial hypertension: a retrospective study. *中国循环杂志*, 31.
- Dimopoulos, K., Peset, A. dan Gatzoulis, M. A. 2008. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. *International journal of cardiology*, 129: 163–171.
- Dinarti, L. K., Hartopo, A. B., Anggrahini, D. W., Sadewa, A. H., Setianto, B. Y. dan Wahab, A. S. 2020. Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia. *Cardiology Research and Practice*, 2020.
- Duffels, M. G. J., Engelfriet, P. M., Berger, R. M. F., van Loon, R. L. E., Hoendermis, E., Vriend, J. W. J., van der Velde, E. T., Bresser, P. dan Mulder, B. J. M. 2007. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. *International journal of cardiology*, 120: 198–204.
- Galiè, N., Chairperson, E. S. C., Humbert, M., Chairperson, E. R. S., Vachiery, J., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A. V., Beghetti, M., Ghofrani, A., Angel, M., Sanchez, G., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L. A., Trindade, P. T., Zompatori, M. dan Hoeper, M. 2015. 2015 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. : 903–975.
- Galie, N., Channick, R. N., Frantz, R. P., Grunig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y. dan McLaughlin, V. V. 2019. Risk stratification and medical therapy of pulmonary arterial hypertension. *The European respiratory journal*, 53.
- Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M. dan Simonneau, G. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. *The New England journal of medicine*, 353: 2148–2157.
- Galie, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., Ghofrani, A., Gomez Sanchez, M. A., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L. A., Trindade, P. T., Zompatori, M. dan Hoeper, M. 2016. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. *Revista espanola de cardiologia (English ed.)*, 69: 177.
- Galie, N., McLaughlin, V. V., Rubin, L. J. dan Simonneau, G. 2019. An overview

- of the 6th World Symposium on Pulmonary Hypertension. *The European respiratory journal*, 53.
- Galie, N., Palazzini, M. dan Manes, A. 2010. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. *European heart journal*, 31: 2080–2086.
- Garg, N., Sharma, M. K. dan Sinha, N. 2007. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. *International journal of cardiology*, 120: 306–313.
- Ghofrani, H. A., Wiedemann, R., Rose, F., Olschewski, H., Schermuly, R. T., Weissmann, N., Seeger, W. dan Grimminger, F. 2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Annals of internal medicine*, 136: 515–522.
- Hascoët, S., Baruteau, A.-E., Humbert, M., Simonneau, G., Jais, X., Petit, J., Laux, D., Sitbon, O., Lambert, V. dan Capderou, A. 2017. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. *The Journal of Heart and Lung Transplantation*, 36: 386–398.
- Hellenkamp, K., Unsöld, B., Mushemi-Blake, S., Shah, A. M., Friede, T., Hasenfuß, G. dan Seidler, T. 2018. Echocardiographic estimation of mean pulmonary artery pressure: a comparison of different approaches to assign the likelihood of pulmonary hypertension. *Journal of the American Society of Echocardiography*, 31: 89–98.
- Hoette, S., Creuzé, N., Günther, S., Montani, D., Savale, L., Jaïs, X., Parent, F., Sitbon, O., Rochitte, C. E. dan Simonneau, G. 2018. RV fractional area change and TAPSE as predictors of severe right ventricular dysfunction in pulmonary hypertension: a CMR study. *Lung*, 196: 157–164.
- Huang, J.-B., Liang, J. dan Zhou, L.-Y. 2012. Eisenmenger syndrome: not always inoperable. *Respiratory care*, 57: 1488–1495.
- Humbert, M., Sitbon, O. dan Simonneau, G. 2004. Treatment of pulmonary arterial hypertension. *The New England journal of medicine*, 351: 1425–1436.
- Ikeda, D., Tsujino, I., Ohira, H., Itoh, N., Kamigaki, M., Ishimaru, S., Sakaue, S. dan Nishimura, M. 2005. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. *Journal of cardiovascular pharmacology*, 45: 286–289.
- Kaemmerer, H., Apitz, C., Brockmeier, K., Eicken, A., Gorenflo, M., Hager, A., de Haan, F., Huntgeburth, M., Kozlik-Feldmann, R. G., Miera, O. dan Diller, G. P. 2018. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. *International journal of cardiology*, 272S: 79–88.
- Kemp, K., Savale, L., O’Callaghan, D. S., Jaïs, X., Montani, D., Humbert, M., Simonneau, G. dan Sitbon, O. 2012. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *The Journal of heart and lung transplantation*, 31: 150–158.
- Kiefer, T. L. dan Bashore, T. 2013. Anatomy of congenital heart disease lesions

- associated with pulmonary arterial hypertension. *Advances in Pulmonary Hypertension*, 11: 166–170.
- Koentartiwi, D. 2014. Efek sildenafil pada hipertensi paru sekunder akibat penyakit jantung bawaan lesi pirau kiri ke kanan= Sildenafil for secondary pulmonary hypertension due to left to right shunt.
- Krisdinarti, L., Hartopo, A. B., Anggrahini, D. W., Sadewa, A. H., Wahab, A. S. dan Setianto, B. Y. 2016. Clinical characteristics of adult uncorrected secundum atrial septal defect: a pilot study. *J Med Sci*, 48: 89–97.
- Kuhr, F. K., Smith, K. A., Song, M. Y., Levitan, I. dan Yuan, J. X.-J. 2012. New mechanisms of pulmonary arterial hypertension: role of Ca(2)(+) signaling. *American journal of physiology. Heart and circulatory physiology*, 302: H1546–62.
- Kukreja, R. C., Salloum, F., Das, A., Ockaili, R., Yin, C., Bremer, Y. A., Fisher, P. W., Wittkamp, M., Hawkins, J., Chou, E., Kukreja, A. K., Wang, X., Marwaha, V. R. dan Xi, L. 2005. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. *Vascular pharmacology*, 42: 219–232.
- Laboratories, A. T. S. C. on P. S. for C. P. F. 2002. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*, 166: 111–117.
- Lau, E. M. T., Giannoulatou, E., Celermajer, D. S. dan Humbert, M. 2017. Epidemiology and treatment of pulmonary arterial hypertension. *Nature Reviews Cardiology*, 14: 603.
- McLaughlin, V. V., Shah, S. J., Souza, R. dan Humbert, M. 2015. Management of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, 65: 1976–1997.
- Michelakis, E. D., Tymchak, W., Noga, M., Webster, L., Wu, X., Lien, D., Wang, S., Modry, D. dan Archer, S. L. 2003. Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension. : 2066–2069.
- Miwa, K., Matsubara, T., Uno, Y., Yasuda, T., Sakata, K., Tsuda, T. dan Kanaya, H. 2007. Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome. *International heart journal*, 48: 417–422.
- Mukhopadhyay, S., Nathani, S., Yusuf, J., Shrimal, D. dan Tyagi, S. 2011. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome—a randomized, placebo-controlled, double-blind crossover study. *Congenital heart disease*, 6: 424–431.
- Myers, P. O., Tissot, C. dan Beghetti, M. 2014. Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. *Circulation journal: official journal of the Japanese Circulation Society*, 78: 4–11.
- Nauser, T. D. dan Stites, S. W. 2001. Diagnosis and treatment of pulmonary hypertension. *American family physician*, 63: 1789–1798.
- Palma, G., Giordano, R., Russolillo, V., Cioffi, S., Palumbo, S., Mucerino, M., Poli, V. dan Vosa, C. 2011. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. *Texas Heart Institute*

journal, 38: 238–242.

- Poms, A. D., Turner, M., Farber, H. W., Meltzer, L. A. dan McGoon, M. D. 2013. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. *Chest*, 144: 169–176.
- Pulido, T., Zayas, N., de Mendieta, M. A., Plascencia, K. dan Escobar, J. 2016. Medical therapies for pulmonary arterial hypertension. *Heart failure reviews*, 21: 273–283.
- Raja, S. G., Danton, M. D., MacArthur, K. J. dan Pollock, J. C. 2006. Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. *Journal of cardiothoracic and vascular anesthesia*, 20: 722–735.
- Ramani, G. V dan Park, M. H. 2010. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. *Drug design, development and therapy*, 4: 61–70.
- Rubin, L. J., Badesch, D. B., Fleming, T. R., Galie, N., Simonneau, G., Ghofrani, H. A., Oakes, M., Layton, G., Serdarevic-Pehar, M., McLaughlin, V. V dan Barst, R. J. 2011. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*, 140: 1274–1283.
- Sastry, B. K. S., Narasimhan, C., Reddy, N. K. dan Raju, B. S. 2004. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. *Journal of the American College of Cardiology*, 43: 1149–1153.
- Schwerzmann, M. dan Pfammatter, J.-P. 2015. Approaching atrial septal defects in pulmonary hypertension. *Expert review of cardiovascular therapy*, 13: 693–701.
- Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G. dan Souza, R. 2019. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *The European respiratory journal*, 53.
- Sitbon, O., Sattler, C., Bertoletti, L., Savale, L., Cottin, V., Jaïs, X., De Groote, P., Chaouat, A., Chabannes, C., Bergot, E., Bouvaist, H., Dauphin, C., Bourdin, A., Bauer, F., Montani, D., Humbert, M. dan Simonneau, G. 2016. Initial dual oral combination therapy in pulmonary arterial hypertension. *European Respiratory Journal* (on-line), 47: 1727 LP – 1736.
- Sommer, R. J., Hijazi, Z. M. dan Rhodes, J. F. J. 2008. Pathophysiology of congenital heart disease in the adult: part I: Shunt lesions. *Circulation*, 117: 1090–1099.
- Souza, R., Jardim, C., Fernandes, C. J. C., Lapa, M. S., Rabelo, R. dan Humbert, M. 2007. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respiratory medicine*, 101: 69–75.
- Trow, T. K. dan McArdle, J. R. 2007. Diagnosis of pulmonary arterial hypertension. *Clinics in chest medicine*, 28: 59–73, viii.
- Velayati, A., Valerio, M. G., Shen, M., Tariq, S., Lanier, G. M. dan Aronow, W. S. 2016. Update on pulmonary arterial hypertension pharmacotherapy. *Postgraduate medicine*, 128: 460–473.
- Vogel, M., Berger, F., Kramer, A., Alexi-Meshkishvili, V. dan Lange, P. E. 1999.

Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. *Heart*, 82: 30–33.

Webb, D. J., Freestone, S., Allen, M. J. dan Muirhead, G. J. 1999. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. *The American journal of cardiology*, 83: 21–28.

Wolfson, A. M., Maitland, M. L., Thomeas, V., Glassner, C. dan Gomberg-Maitland, M. 2017. A Serial NT-proBNP Model to Improve Prognostication in Patients with Pulmonary Arterial Hypertension. *J Clin Exp Cardiol*, 8: 2.

Yao, A. 2016. “Treat-and-Repair” Strategy for Atrial Septal Defect and Associated Pulmonary Arterial Hypertension. , 80: 3–5.